The MACD is positive at 0.313, indicating bullish momentum, while the RSI at 71.555 is neutral. Moving averages are converging, suggesting consolidation. Key support is at 27.51, and resistance is at 30.531. The stock is trading near resistance, but the overall trend is stable with a slight upward bias.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate bullish sentiment among options traders.

Technical Summary

Sell

Buy

Positive Catalysts

FDA approval of Aqvesme with a broad label for thalassemia treatment.
Strong hedge fund buying activity, up 297.63% last quarter.
Revenue growth of 86.09% YoY in Q4
Positive analyst sentiment with multiple price target increases and Buy ratings.

Neutral/Negative Catalysts

Net income remains negative at -108.03M, though it has improved YoY.
No recent news or Congress trading data to provide additional sentiment.
Stock trend analysis suggests a minor probability of short-term decline (-1.32% over the next month).

Financial Performance

In Q4 2025, revenue increased by 86.09% YoY to $19.97M. Net income improved by 11.93% YoY but remains negative at -$108.03M. EPS increased by 9.47% YoY to -1.85. Gross margin improved to 90.59%, up 2.64% YoY, indicating strong operational efficiency.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are optimistic about AGIO, with multiple firms raising price targets recently. Targets range from $25 (JPMorgan) to $62 (H.C. Wainwright). The approval of Aqvesme and its pricing strategy have been well-received, with most analysts maintaining Buy or Outperform ratings.

9 Analyst Rating

Wall Street analysts forecast AGIO stock price to rise

6 Buy

3 Hold

0 Sell

Moderate Buy

Current: 30.230

Low

Averages

36.14

High

Current: 30.230

Low

Averages

36.14

High

JPMorgan

Neutral

maintain

$20 -> $25

AI Analysis

2026-01-06

Reason

JPMorgan

Price Target

$20 -> $25

AI Analysis

2026-01-06

maintain

Neutral

Reason

JPMorgan raised the firm's price target on Agios Pharmaceuticals to $25 from $20 and keeps a Neutral rating on the shares. The firm updated the company's model post the approval of Aqvesme.

BofA

Buy

maintain

$34 -> $35

2026-01-06

Reason

BofA

Price Target

$34 -> $35

2026-01-06

maintain

Buy

Reason

BofA raised the firm's price target on Agios Pharmaceuticals to $35 from $34 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AGIO

Unlock Now

AGIO Should I Buy

AGIO Should I Buy

Should You Buy Agios Pharmaceuticals Inc (AGIO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch